The introduction of mutualisms into assembled communities increases their connectance and complexity while decreasing their richness. by Gui Araujo (22170819)

“…Each sample is a simulation of the entire assembly process for a scenario. Parameter values: interaction strengths were drawn from a half-normal distribution of zero mean and a standard deviation of 0.2, and strength for consumers was made no larger than the strength for resources. …”

Average stability values (mean ± standard deviation) and statistical results. by Hyung Suk Yang (20442438)

Subjects:

DHE reports decreased cholesterol uptake by ∆<i>mceG</i> Mtb. by Yue Chen (73753)

Participant demographics. * P-values were determined using Fisher-Freeman-Halton test when contingency tables are larger than 2 × 2. by Elie Mulhem (22537863)

Subjects:

Mean ± SD values of unipedal stance parameters evaluated at the different time points of the postural training session. by Cristina Dolciotti (16317330)

Subjects:

Youthful systemic milieu in young recipients decreased apoptosis and oxidative stress damage in allografts, and promoted proliferation. by Chengjun Yu (12136227)

MAP3K1, MAPK11, and PPP2R1A knockdown decreased ECM internalisation. by Montserrat Llanses Martinez (17797522)

PRCC values (with <i>p</i>-values in parentheses) for the median final population size and difference in mean MSI at the final time, without weevil predation and with weevil predat... by Alexandra M. Campbell (3284094)

Subjects:

Estimated mean values for light interception. by Torsten Schober (20485754)

Subjects:

Force analysis of the system. by Jianbo Jia (717814)

Subjects:

The working principle of the Welleader system. by Jianbo Jia (717814)

Subjects:

Local mechanism diagram of Welleader system. by Jianbo Jia (717814)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Lymphocytes decreased in mouse pneumonia model. by Qi Xu (134661)

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects: